John T., Grohé C., Goldman J.W., Shepherd F.A., de Marinis F., Kato T., Wang Q., Su W.-C., Choi J.H., Sriuranpong V., Melotti B., Fidler M.J., Chen J., Albayaty M., Stachowiak M., Taggart S., Wu Y.-L., Tsuboi M., Herbst R.S., Majem M.. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. Journal of Thoracic Oncology. 2023; 18(9)DOI:10.1016/j.jtho.2023.05.015. PMID:37236398. IF:21.100(Q1/1D).

Tsutani Y., Goldman J.W., Dacic S., Yatabe Y., Majem M., Huang X., Chen A., van der Gronde T., He J.. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer. 2023; 24(4)DOI:10.1016/j.cllc.2023.02.002. PMID:36872181. IF:3.300(Q2/4D).

Herbst R.S., Wu Y.-L., John T., Grohe C., Majem M., Wang J., Kato T., Goldman J.W., Laktionov K., Kim S.-W., Yu C.-J., Vu H.V., Lu S., Lee K.Y., Mukhametshina G., Akewanlop C., De Marinis F., Bonanno L., Domine M., Shepherd F.A., Urban D., Huang X., Bolanos A., Stachowiak M., Tsuboi M.. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(10)DOI:10.1200/JCO.22.02186. PMID:36720083. IF:42.100(Q1/1D).

Provencio M., Ortega A.L., Coves-Sarto J., Calvo V., Marsé-Fabregat R., Dómine M., Guirado M., Carcereny E., Fernández N., Álvarez R., Blanco R., León-Mateos L., Sánchez-Torres J.M., Sullivan I.G., Cobo M., Sánchez-Hernández A., Massuti B., Sierra-Rodero B., Mártinez-Toledo C., Serna-Blasco R., Romero A., Cruz-Bermúdez A.. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial. JAMA Oncology. 2023; 9(3)DOI:10.1001/jamaoncol.2022.5959. PMID:36520426. IF:22.300(Q1/1D).

Grünwald V., Powles T., Eto M., Kopyltsov E., Rha S.Y., Porta C., Motzer R., Hutson T.E., Méndez-Vidal M.J., Hong S.-H., Winquist E., Goh J.C., Maroto P., Buchler T., Takagi T., Burgents J.E., Perini R., He C., Okpara C.E., McKenzie J., Choueiri T.K.. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Frontiers in Oncology. 2023; 13DOI:10.3389/fonc.2023.1223282. PMID:37664025. IF:3.500(Q2/4D).

Fiala O., Buti S., Takeshita H., Okada Y., Massari F., Palacios G.A., Dionese M., Scagliarini S., Büttner T., Fornarini G., Myint Z.W., Galli L., Souza V.C., Pichler R., De Giorgi U., Quiroga M.N.G., Gilbert D., Popovic L., Grande E., Mammone G., Berardi R., Crabb S.J., Molina-Cerrillo J., Freitas M., Luz M., Iacovelli R., Calabrò F., Tural D., Atzori F., Küronya Z., Chiari R., Campos S., Caffo O., Fay A.P., Kucharz J., Zucali P.A., Rinck J.A., Zeppellini A., Bastos D.A., Aurilio G., Mota A., Trindade K., Ortega C., Sade J.P., Rizzo M., Vau N., Giannatempo P., Barillas A., Monteiro F.S.M., Dauster B., Cattrini C., Nogueira L., de Carvalho Fernandes R., Seront E., Aceituno L.G., Grillone F., Cutuli H.J., Fernandez M., Bassanelli M., Roviello G., Abahssain H., Procopio G., Milella M., Kopecky J., Martignetti A., Messina C., Caitano M., Inman E., Kanesvaran R., Herchenhorn D., Santini D., Manneh R., Bisonni R., Zakopoulou R., Mosca A., Morelli F., Maluf F., Soares A., Nunes F., Pinto A., Zgura A., Incorvaia L., Ansari J., Zabalza I.O., Landmesser J., Rizzo A., Mollica V., Sorgentoni G., Battelli N., Porta C., Bellmunt J., Santoni M.. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; 72(11)DOI:10.1007/s00262-023-03518-z. PMID:37676282. IF:4.600(Q1/3D).

Wakelee H., Liberman M., Kato T., Tsuboi M., Lee S.-H., Gao S., Chen K.-N., Dooms C., Majem M., Eigendorff E., Martinengo G.L., Bylicki O., Rodríguez-Abreu D., Chaft J.E., Novello S., Yang J., Keller S.M., Samkari A., Spicer J.D.. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(6)DOI:10.1056/NEJMoa2302983. PMID:37272513. IF:96.300(Q1/1D).

Tibau A., Martínez M.T., Ramos M., De La Cruz-Merino L., Santaballa A., O’Connor M., Martínez-Jañez N., Moreno F., Fernández I., Virizuela J.A., Alarcón J., de La Haba-Rodríguez J., Sánchez-Rovira P., Albacar C.R., Bueno Muiño C., Kelly C., Casas M., Bezares S., Rosell L., Albanell J.. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359221148921. PMID:36743520. IF:4.300(Q2/3D).